Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
University of British Columbia
$60,000.00
Paracrine and autocrine IL-6 as drivers of treatment resistance in medulloblastoma
EF 2021-22
Résumé
Brain tumors represent the deadliest forms of childhood cancers. Owing to its location within the cortex of the still developing brain, complete tumor removal by resection is often not achieved. Thus, the mainstay for treatment remains chemo and radiation therapy. A challenge is finding the balance of treatment dosage to maximize tumor cell killing while minimizing unwanted damage to healthy tissues. Tumor cells that survive therapy give rise to disease relapse, and the relapsed form are often resistant to further treatments. In addition, relapsed tumors may become metastatic, the process whereby the tumor grows in multiple satellite sites distant from the original tumor. Strategies to improve brain tumor treatment that minimize the chances of relapse are urgently needed. The most common form of pediatric brain tumor is medulloblastoma (MB), of which the subtype known as group 3 MB is the most aggressive, with highest rates of metastasis, and lowest rates of survival. We discovered that group 3 MB cells exposed to ‘bad’ cytokines released by immune cells found in the brain rapidly show chemoresistance, as well as increased migration and invasion abilities indicative of metastatic potential. Our research will lead to strategic discoveries on how to block the ‘bad’ cytokines, and in doing so, prevent MB from becoming chemoresistant, thus minimizing chances of tumor relapse.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
468060
Name
Lim Chinten J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Paracrine and autocrine IL-6 as drivers of treatment resistance in medulloblastoma
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Brain And Nervous System; Chemotherapy And Radiotherapy; Childhood And Young Adult
; Tumour Progression And Metastasis
Abstract
Brain tumors represent the deadliest forms of childhood cancers. Owing to its location within the cortex of the still developing brain, complete tumor removal by resection is often not achieved. Thus, the mainstay for treatment remains chemo and radiation therapy. A challenge is finding the balance of treatment dosage to maximize tumor cell killing while minimizing unwanted damage to healthy tissues. Tumor cells that survive therapy give rise to disease relapse, and the relapsed form are often resistant to further treatments. In addition, relapsed tumors may become metastatic, the process whereby the tumor grows in multiple satellite sites distant from the original tumor. Strategies to improve brain tumor treatment that minimize the chances of relapse are urgently needed. The most common form of pediatric brain tumor is medulloblastoma (MB), of which the subtype known as group 3 MB is the most aggressive, with highest rates of metastasis, and lowest rates of survival. We discovered that group 3 MB cells exposed to ‘bad’ cytokines released by immune cells found in the brain rapidly show chemoresistance, as well as increased migration and invasion abilities indicative of metastatic potential. Our research will lead to strategic discoveries on how to block the ‘bad’ cytokines, and in doing so, prevent MB from becoming chemoresistant, thus minimizing chances of tumor relapse.
Competitiondate
202202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lim, Chinten J
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $60,000~ $0~